SK Bioscience (302440) Stock Price, Fundamentals & Analysis
Price
35,750 KRW
0%
Last trade: Sep 23, 2026, 03:30 PM GMT+9
Updated: Sep 27, 2026, 06:31 PM GMT+9
Price history
Over the past year 302440 traded between 32,500 KRW and 60,100 KRW, closing at 35,750 KRW on Sep 23, 2026.
Key statistics
| Market cap | 2.8T KRW |
|---|---|
| Forward P/E | -37 |
| Payout ratio | 0% |
| 52-week range | 31,800 – 61,300 |
| 52-week change | -24.2% |
| Beta | 0.88 |
| Revenue (TTM) | 659.27B KRW |
| Revenue growth (YoY) | -3.8% |
| Gross margin | 14.2% |
| Operating margin | -10.1% |
| Profit margin | -12.8% |
| Return on equity | -4.2% |
| Debt / equity | 27.1 |
| Volume | 59,220 |
| Average volume | 84,397 |
| Next earnings | Oct 26, 2026 |
| Exchange | KSE |
Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seongnam-si, South Korea
- Website
- skbioscience.co.kr
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.
Overview
What 302440 does
SK Bioscience (302440) is a stock listed on the Korea Exchange in the Healthcare sector, specifically the Biotechnology industry. Headquartered in Seongnam-si, South Korea, the company researches, produces, and distributes vaccines and biopharmaceuticals. Its portfolio includes products such as Skycellflu, a cell-cultured influenza vaccine; Skyzoster, a shingles vaccine; Sky Baricella for chickenpox prevention; and pneumococcal vaccines for both adults and infants. The company is also developing vaccines for rotavirus, cervical cancer, typhoid, and COVID-19, with several candidates in clinical trials. SK Bioscience is a subsidiary of SK Chemicals Co., Ltd.
Key numbers explained
- The current price of 35,750 KRW is the latest trading price on the Korea Exchange.
- The marketCap of 2.8T KRW represents the total market value of all outstanding shares.
- The forward P/E ratio of -37 is calculated using expected future earnings; a negative value indicates the company is currently expected to report a loss.
- The dividend yield is 0%, meaning the company pays no share of its earnings as dividends.
- The beta of 0.88 suggests the stock's price tends to be less volatile than the overall market.
- The 52-week range of 31,800 – 61,300 shows the lowest and highest traded prices over the past year.
- The debt-to-equity ratio of 27.1% compares the company's total debt to its shareholder equity.
What to watch
Investors tracking SK Bioscience may monitor its pipeline of vaccines in clinical trials, as successful developments can influence future revenue. The company's position within the Korean biotechnology sector places it among peers like Celltrion (068270), Samsung Biologics (207940), and SK Biopharm (326030). Broader sector trends, such as government healthcare spending and global vaccine demand, can also affect the stock's performance. The next earnings report is scheduled for Oct 26, 2026.
Latest news & filings
No recent headlines.
Frequently asked questions
Does 302440 pay a dividend?
No, the share of earnings paid out as dividends is 0%.
What is the 302440 P/E ratio?
The forward P/E ratio is -37, based on expected earnings.
Where can I buy 302440?
It is listed and traded on the Korea Exchange.
What is the market cap of 302440?
The market capitalization is 2.8 trillion KRW.
What does the beta of 0.88 mean for 302440?
A beta of 0.88 indicates the stock is generally less volatile than the overall market.
Related
More on 302440
Track 302440 in your portfolio
Hold 302440 at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free